Patent Law Weblog
recent posts
- Quo Vadis mRNA Vaccine Technology? The State of the IP Lawsuits
- Moderna Settles Patent Litigation with Arbutus et al.
- USPTO and DOJ Statement of Interest in Collision Communications: Another Thumb on the Scale in Favor of NPE Patent Plaintiffs
- Oasis Tooling, Inc. v. Siemens Industry Software Inc. (Fed. Cir. 2026)
- Why AI Will Not Take Over the World
about
Category: Licensing
-
By Kevin E. Noonan — In just the latest in a series of developments unwelcomed by Western drug companies, Brasil has threatened to distribute a generic version of Merck & Co.’s anti-AIDS drug efavirenz (Stocrin®). This action is consistent with earlier steps taken by Brasil, as well as Thailand, that thwart the intentions…
-
By Christopher P. Singer — In an April 26, 2007 press release SciClone Pharmaceuticals Inc. announced that it acquired exclusive rights in the U.S. and Canada to develop and commercialize a compound in the clinical stage for treatment of pancreatic cancer. The drug, RP101, was brought to Phase I clinical trials as a…
-
By Donald Zuhn — Bristol-Myers Squibb Co. and Pfizer Inc. announced today that the companies will be entering into two separate collaborations. In the first, the two companies will be working together to develop and commercialize Bristol-Myers Squibb’s anticoagulant, apixaban. In the second, the collaboration will focus on the research, development, and commercialization…
-
By Christopher P. Singer — Luminex Corporation announced that it received a non-exclusive license from Johns Hopkins University with rights to use the University’s patented cystic fibrosis (CF) genetic markers. CF is a chronic autosomal recessive disorder affecting the lungs and digestive tract caused by mutations in the cystic fibrosis transmembrane conductance regulator…
-
By Jason Derry — Cytos Biotechnology AG has granted a worldwide, exclusive license to Novartis to develop, manufacture, and commercialize its therapeutic vaccine for nicotine addiction, CYT002-NicQb. The vaccine is currently in Phase II clinical development. Cytos may receive upfront and milestone payments, as well as royalty payments, based on the successful commercial…
-
By Donald Zuhn — SinoBiomed announced today that the U.S. Patent & Trademark Office has issued U.S. Patent No. 7,101,556, which is directed to fusion proteins comprising the Plasmodium merozoite surface protein-1 (MSP1) and the Plasmodium apical membrane antigen 1 (AMA-1) and the production of anti-malarial vaccines using such proteins. In its release,…
-
By Christopher P. Singer — AstraZeneca PLC announced on Monday that it plans to acquire MedImmune Inc. in a deal estimated to be worth about $15 billion. AstraZeneca expects that this acquisition, in combination with its earlier acquisition of Cambridge Antibody Technology (CAT) will place it among the top biologics companies in the…
-
By Donald Zuhn — Last Thursday, Novartis AG announced that it had signed an exclusive license with Antisoma PLC for the worldwide rights to the cancer therapeutic AS1404. AS1404 is a member of a class of compounds known as small molecule vascular disrupting agents (VDAs). VDAs, which selectively disrupt established blood vessels supporting…
-
By Jason Derry — Array BioPharma has announced that AstraZeneca has dosed a patient with its MEK inhibitor, ARRY-704, in a Phase I clinical trial. By dosing the first patient, Array BioPharma is now entitled to a $2 million milestone payment from AstraZeneca. ARRY-704 is an orally active MEK-inhibitor with tumor suppressive activity. …
-
By Donald Zuhn — On Tuesday, Abbott announced that it had reached an agreement with World Health Organization (WHO) Director General Margaret Chan to reduce the price of its Kaletra/Aluvia (lopinavir/ritonavir) AIDS drugs in the developing world. In particular, Abbott will be offering the drugs to about forty low and low-middle income countries…
Patent Docs 